ibandronic acid has been researched along with vitamin d 2 in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (33.33) | 29.6817 |
2010's | 2 (66.67) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Daphnis, E; Karamitopoulou, E; Karkavitsas, N; Katsipi, I; Kyriazis, J; Stratigis, S; Stylianou, K | 1 |
Kõks, S; Laius, O; Maasalu, K; Märtson, A | 1 |
1 review(s) available for ibandronic acid and vitamin d 2
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 other study(ies) available for ibandronic acid and vitamin d 2
Article | Year |
---|---|
Parathyromatosis and the challenge of treatment.
Topics: Adult; Bone Density Conservation Agents; Diphosphonates; Disease Progression; Ergocalciferols; Female; Humans; Hypercalcemia; Hyperparathyroidism; Ibandronic Acid; Kidney Failure, Chronic; Renal Dialysis; Reoperation | 2006 |
Use of drugs against osteoporosis in the Baltic countries during 2010-2014.
Topics: Alendronate; Baltic States; Bone Density Conservation Agents; Calcium Channel Blockers; Denosumab; Diphosphonates; Drug Utilization; Ergocalciferols; Fractures, Bone; Humans; Ibandronic Acid; Osteoporosis; Risedronic Acid | 2016 |